Trials / Recruiting
RecruitingNCT06941870
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efanesoctocog alfa | Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous |
Timeline
- Start date
- 2025-09-23
- Primary completion
- 2027-10-25
- Completion
- 2027-10-25
- First posted
- 2025-04-24
- Last updated
- 2025-11-18
Locations
13 sites across 4 countries: United States, Canada, Japan, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06941870. Inclusion in this directory is not an endorsement.